TP A2: Identification of novel B cell inhibitory compounds

Controlling antibody production by B cell derived plasma cells is one approach for the treatment of autoimmune disorders. However, systemic use of corticosteroids has been still the mainstream of the therapy despite the potential severe adverse effects. In addition, newer treatments including monoclonal antibodies against CD20 expressing B cells, e.g. Rituximab©, are not universally applicable, most likely due to high cost, long-term efficacy and safety.      

Based on these considerations, my PhD project aims to identify immunomodulatory agents that affect B cell function. For this purpose the effect of the compounds  on B cell proliferation and immunoglobulin (Ig) production will be investigated.